After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Cyclacel Pharmaceuticals shares are trading higher by 77% during Friday's session. The company announced a securities purchase agreement with investor David Lazar.
CYCC stock results show that Cyclacel Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
